<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02406781</url>
  </required_header>
  <id_info>
    <org_study_id>IB 2014-04</org_study_id>
    <secondary_id>2014-004568-39</secondary_id>
    <nct_id>NCT02406781</nct_id>
  </id_info>
  <brief_title>Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial</brief_title>
  <acronym>PEMBROSARC</acronym>
  <official_title>Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Immune Design</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter study assessing the efficacy of different therapeutic strategy in
      patients with advanced sarcomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2 trial with 7 strata :

        -  Leiomyosarcoma : 33 patients

        -  Undifferentiated sarcoma : 33 patients

        -  Sarcomas others : 33 patients

        -  Osteosarcoma : 33 patients

        -  GIST : 31 patients

        -  Advanced soft-tissue sarcoma with immune signature: 32 patients

        -  Metastatic soft-tissue sarcoma: 32 patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the efficacy of MK3475 associated with Metronomic Cyclophosphamide per RECIST v1.1 criteria</measure>
    <time_frame>6 months</time_frame>
    <description>This primary objective of this study is to assess the efficacy of MK3475 and Metronomic Cyclophosphamide (CP) independently for 6 strata as per RECIST v1.1 criteria :
In terms of 6-month objective response and 6-months non progression for:
Advanced leiomyosarcoma
Advanced undifferentiated sarcoma
Advanced other sarcoma
Advanced osteosarcoma
In terms of·6-month non progression for:
Advanced GIST
Advanced soft-tissue sarcoma with immune signature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the efficacy of MK3475 associated with Metronomic Cyclophosphamide and G100 per RECIST v1.1 criteria</measure>
    <time_frame>6 months</time_frame>
    <description>This primary objective of this study is to assess the efficacy of MK3475 and Metronomic Cyclophosphamide (CP) and G100 as per RECIST v1.1 criteria, in terms of 6-months non progression for metastatic soft-tissue sarcoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment strategy in terms of Best overall response</measure>
    <time_frame>participants will be followed for the duration of treatment, an expected average of 6-months</time_frame>
    <description>Assessment of the efficacy of the treatment strategy in terms of best overall response (as per RECIST v1.1 criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment strategy in terms of Progression-free Survival</measure>
    <time_frame>Progression-free survival assessed at 12 months</time_frame>
    <description>Assessment of the efficacy of the treatment strategy in terms of 1-year progression-free survival (as per RECIST v1.1 criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment strategy in terms of Immune_related Response</measure>
    <time_frame>Immune-related response assessed at 6 months</time_frame>
    <description>Assessment of the efficacy of the treatment strategy in terms of 6-months immune-related response (as per Wolchok 2009)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment strategy in terms of Overall Survival.</measure>
    <time_frame>Overall survival assessed at 12 months</time_frame>
    <description>Assessment of the efficacy of the treatment strategy in terms of 1-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of the treatment strategy.Toxicity graded using the Common Terminology Criteria for Adverse Events version 4</measure>
    <time_frame>Throughout the treatment period, an average of 6 months</time_frame>
    <description>Toxicity graded using the Common Terminology Criteria for Adverse Events version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of blood cytokines levels (TNFγ, TNFα, TGFβ, IL2, 4, 6, 10) (ELISA)</measure>
    <time_frame>Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of blood VEGF, Svegfr2 and TPS-1 levels (ELISA)</measure>
    <time_frame>Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of lymphocytes subpopulations monitoring, CD8+/Treg ratio (flow cytometry)</measure>
    <time_frame>Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of Plasma levels of Kynurenine and Kynurenine to Tryptophan ratio (ELISA and LC/MS)</measure>
    <time_frame>Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">227</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment strategy A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of MK3475 with Metronomic CP. MK3475 will be administered intraveinously. Metronomic CP (Cyclophosphamide) will be adminstered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment strategy B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of MK3475 with Metronomic CP and G100. MK3475 will be administered intravenously. Metronomic CP (Cyclophosphamide) will be administered orally. G100 will be administered by intra-tumoral injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of MK3475 with Metronomic CP</intervention_name>
    <description>Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.
MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.</description>
    <arm_group_label>Treatment strategy A</arm_group_label>
    <other_name>Pembrolizumab, Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of MK3475 with Metronomic CP and G100</intervention_name>
    <description>Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.
MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.
G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).
A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.</description>
    <arm_group_label>Treatment strategy B</arm_group_label>
    <other_name>Pembrolizumab, Endoxan, GLA-SE (glucopyranosyl lipid adjuvant-stable emulsion).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histology : Leiomyosarcoma, or UPS, or other sarcoma, or GIST or osteosarcoma, or
             soft-tissue sarcoma with presence of tertiary lymphoid structures (stratum 6)
             histologically confirmed by central review.

          2. Advanced non resectable / metastatic disease for strata 1 to 6. For stratum 7: locally
             advanced or metastatic disease with at least one injectable lesion.

          3. Documented progression according to RECIST criteria. Progression on the last line of
             treatment should be confirmed by central review with two radiological assessments
             identical obtained at less than 6 months interval within the 12 months before
             inclusion.

          4. For stratum 5, documented disease progression according to RECIST criteria after the
             first line imatinib and second line sunitinib.

          5. Have provided tissue of a tumor lesion from an archival tissue sample obtained on
             metastasis or on locally advanced disease, or newly obtained core or excisional
             biopsy. For strata 6 and 7, tissue &lt; 3 months old and with no subsequent treatment
             since or from a newly obtained biopsy.

          6. For strata 1, 2, 3 and 6: no more of four previous lines of systemic therapy for
             metastatic disease and no more than 2 previous line for stratum 7.

          7. Age ≥ 18 years.

          8. ECOG performance status ≤ 1.

          9. Measurable disease according to RECIST v1.1 outside any previously irradiated field.
             At least one site of disease must be uni-dimensionally ≥ 10 mm.

         10. Life expectancy &gt; 3 months (except for stratum 7 &gt; 6 months).

         11. ≥ 1 previous line (s) of chemotherapy in the palliative setting for strata 1 to 5. For
             other strata, participant must have advanced disease and must not be a candidate for
             other approved therapeutic regimen known to provide significant clinical benefit based
             on investigator judgement.

         12. No symptomatic central nervous system disease.

         13. No chronic use of glucocorticoids.

         14. Adequate hematological, renal, metabolic and hepatic function:

               1. Hemoglobin ≥ 9 g/dl (patients may have received prior red blood cell
                  transfusion); ANC ≥ 1.5 x 109/l and platelet count ≥ 100 x 109/l. For stratum 7:
                  lymphocyte count ≥ 0.5.109 /l

               2. ALT and AST ≤ 2.5 x upper limit of normality (ULN) (≤ 5 in case of liver
                  metastasis)

               3. Total bilirubin ≤ 1.5 x ULN OR Direct bilirubin ≤ ULN for subjects with total
                  bilirubin levels ≥ 1.5 x ULN

               4. Albumin ≥ 25g/l

               5. Serum creatinine ≤ 1.5 x ULN OR CrCl ≥ 60 ml/min for subject with creatinine
                  levels ≥ 1.5 x ULN,

               6. Creatine phosphokinase ≤ 2.5 x ULN

               7. INR ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT
                  or PTT is within therapeutic range of intended use of anticoagulants

               8. aPTT ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT
                  or PTT is within therapeutic range of intended use of anticoagulants

         15. No prior or concurrent malignant disease diagnosed or treated in the last 2 years
             except for adequately treated in situ carcinoma of the cervix, basal or squamous skin
             cell carcinoma, or in situ transitional bladder cell carcinoma.

         16. At least three weeks since last chemotherapy, immunotherapy or any other
             pharmacological treatment and/or radiotherapy.

         17. Recovery to grade ≤ 1 from any adverse event from previous treatment (excluding
             alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2 (NCI-CTCAE, v
             4.0).

         18. Women of childbearing potential must have a negative serum pregnancy test within 72
             hours prior to receiving the first dose of study medication. Both women and men must
             agree to use a medically acceptable method of contraception throughout the treatment
             period and for four months after discontinuation of treatment. Acceptable methods for
             contraception include intrauterine device, oral contraceptive, subdermal implant and
             double barrier. Subjects of childbearing potential are those who have not been
             surgically sterilized or have not been free from menses for ≥ 1 year.

         19. Voluntary signed and dated written informed consents prior to any specific study
             procedure.

         20. Patients with a French social security in compliance with the Law relating to
             biomedical research (Article 1121-11 of French Public Health Code).

        Exclusion Criteria:

          1. Previous treatment with MK3475 or CP or G100.

          2. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically
             targeting T-cell co-stimulation or checkpoint pathways).

          3. Evidence of progressive or symptomatic central nervous system (CNS) or leptomeningeal
             metastases.

          4. Men or women of childbearing potential who are not using an effective method of
             contraception as previously described; women who are pregnant or breast feeding.

          5. Participation to a study involving a medical or therapeutic intervention in the last
             30 days.

          6. Previous enrolment in the present study.

          7. Patient unable to follow and comply with the study procedures because of any
             geographical, familial, social or psychological reasons.

          8. Known hypersensitivity to any involved study drug or of its formulation components.

          9. Has an active autoimmune disease requiring systemic treatment within the past 3 months
             or a documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or
             resolved childhood asthma/atopy would be an exception to this rule. Subjects that
             require intermittent use of bronchodilators or local steroid injections would not be
             excluded from the study. Subjects with hypothyroidism stable on hormone replacement or
             Sjorgen's syndrome will not be excluded from the study.

         10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial
             treatment.

         11. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced
             pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening
             chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is
             permitted.

         12. Has known active hepatitis B or hepatitis C.

         13. Has a known history of HIV (HIV1/2 antibodies).

         14. Has received a live vaccine within 30 days prior to the first dose of trial treatment.

         15. For strata 6 to 7:

               -  patients with oral anticoagulation therapy

               -  known urinary tract obstruction

               -  previous allogenic bone marrow transplant

               -  has an active infection requiring systemic treatment within 14 days prior to
                  study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine ITALIANO, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine ITALIANO, MD, PhD</last_name>
    <email>a.italiano@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Mathoulin-Pelissier, MD,PhD</last_name>
    <email>s.mathoulin-pelissier@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ITALIANO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antoine ITALIANO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Penel</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Penel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves BLAY, MD-PHD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François BERTUCCI</last_name>
    </contact>
    <investigator>
      <last_name>François BERTUCCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Piperno-Neumann</last_name>
    </contact>
    <investigator>
      <last_name>Sophie Piperno-Neumann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle BOMPAS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuelle BOMPAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine CHEVREAU</last_name>
    </contact>
    <investigator>
      <last_name>Christine CHEVREAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel LE CESNE</last_name>
    </contact>
    <investigator>
      <last_name>Axel Le CESNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efficacy of MK 3475 with Metronomic Cyclophosphamide</keyword>
  <keyword>Advanced Sarcomas</keyword>
  <keyword>Leiomyosarcoma</keyword>
  <keyword>Undifferentiated Sarcoma</keyword>
  <keyword>Other Sarcoma</keyword>
  <keyword>GIST</keyword>
  <keyword>Osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

